# Regeneron Ventures

Regeneron Ventures is a Venture Capital based in New York, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2023
- **Assets under management:** $500M – $1B (Altss estimate)
- **Website:** regeneronventures.com
- **LinkedIn:** https://www.linkedin.com/company/regeneron-ventures

## Regulatory record

- **Reports private funds:** No

## About

Regeneron Ventures is the venture arm of Regeneron, based in Tarrytown, New York. It invests in small and medium-sized companies. Regeneron Ventures has made 13 investments, including a Series A investment in Think Bioscience on January 20, 2026.

## Sectors

- Digital Health
- AI/ML
- Enterprise Software
- Industrial Tech

## People

- Jay Markowitz — Senior Managing Director
- Michael Aberman — Senior Managing Director

## Questions

### Who runs investment decisions at Regeneron Ventures?

Senior Managing Directors Jay Markowitz and Michael Aberman jointly lead the firm. Markowitz spent over a decade at Takeda Ventures, and Aberman previously served as an analyst and portfolio manager at The Column Group. The investment committee operates independently of Regeneron Pharmaceuticals' corporate development team.

### Are Regeneron Ventures' portfolio companies required to partner with Regeneron Pharmaceuticals?

No. Regeneron Ventures invests with a financial return mandate, not a strategic synergy mandate. Portfolio companies are not obligated to align with Regeneron's internal R&D programs or enter into licensing agreements with the parent corporation.

### What is the relationship between Regeneron Ventures and Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals is the sole limited partner in Regeneron Ventures, providing a $500 million capital commitment. However, the venture firm operates with its own investment committee, independent decision-making authority, and a mandate to invest across the life sciences ecosystem without preferential treatment toward the parent company.

### How does Regeneron Ventures source deal flow?

Deal sourcing combines the networks of its Senior Managing Directors, both of whom have deep ties in venture capital and biotechnology, with inbound opportunities generated through Regeneron's brand recognition. The firm does not publicly describe a formal academic-institution or accelerator-sourcing partnership.

### Is Regeneron Ventures raising external LP capital?

No. The firm was capitalized entirely by Regeneron Pharmaceuticals and has not indicated any plans to open the fund to external limited partners. This single-LP structure allows the team to deploy capital without the time and overhead of multi-year fundraising cycles.

## Related profiles

- [Regeneration.vc](https://altss.com/profile/regenerationvc)
- [Regional Kyosai Capital](https://altss.com/profile/regional-kyosai-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/regeneron-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology